In honor of World Blindness Awareness Month, "GMA" is spotlighting a breakthrough gene therapy that's helping some blind ...
Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
Pharmaceutical Technology on MSN
Eli Lilly buys Adverum in eye disease gene therapy punt
Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...
FDA moves to speed biosimilar approvals by eliminating comparative studies, aiming to lower drug costs and increase ...
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...
The U.S. Food and Drug Administration has placed a clinical hold on Intellia Therapeutics' two late-stage trials testing an ...
Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...
However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback